A Novel β-lactam/β-lactamase Inhibitor: Ceftolozane/tazobactam

• Main Author: Kıvanç ŞEREFHANOĞLU
• Format: Article
• Language: Turkish
• Published: Galenos Yayinevi 2019-12-01
• Series: Mediterranean Journal of Infection, Microbes and Antimicrobials
• Subjects: cre; esbl; hemodialysis; chronic kidney disease; complicated intra-abdominal infections
• Online Access: http://mjima.org/text.php?&id=165

Ceftolozane/tazobactam is a novel generation cephalosporin and β-lactamase inhibitor combination antibiotic. It was approved for the treatment of adults (18 years and older) with complicated intraabdominal infections used in combination with metronidazole and complicated urinary tract infections by the United States Food and Drug Administration. Its primary activity is against multidrug-resistant Pseudomonas aeruginosa and other aerobic Gram-negative bacteria. The main characteristic features of the antibiotic include: (1) a greater affinity for penicillin-binding proteins produced by P. aeruginosa; (2) better outer membrane permeability that displays resistance mechanisms against upregulation of efflux pumps, and (3) effectiveness against pathogens producing AmpC β-lactamases, primitive b-lactamases (TEM-1, TEM-2, SHV-1, and OXA-1), and extended spectrum β-lactamases. However, it is not effective against pathogens producing metallo-β-lactamases and Klebsiella pneumoniae carbapenemases. Ceftolozane/tazobactam is promising for difficult-to-treat infections caused by multidrug-resistant Gram-negative bacteria. Herein, the features of ceftolozane/tazobactam, including its pharmacokinetics, antimicrobial spectrum, and data from recent clinical studies are reviewed.